REG - Cambridge Cognition - Directorate Change

Cambridge Cognition HoldingsAnnouncement

03/08/2022 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220803:nRSC8214Ua&default-theme=true

RNS Number : 8214U  Cambridge Cognition Holdings PLC  03 August 2022

3 August 2022

Cambridge Cognition Holdings Plc

 

("Cambridge Cognition", the "Company" or the "Group")

 

Directorate Change

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce that further
to the announcement of 6 April 2022, Stephen Symonds, Chief Financial Officer,
has been appointed to the Board of Cambridge Cognition as an Executive
Director with immediate effect.

 

Stephen was previously the CFO of Envigo, a provider of pre-clinical services
to the pharmaceutical industry, where he spent eight years.  Prior to that,
Stephen spent a decade with KPMG, working on a wide-ranging portfolio of
clients.

 

Steven Powell, Chairman of the Company, commented: "We are delighted that
Stephen is joining the Board. He has extensive relevant experience and has
fitted in very well with the team since joining the Company in April this
year."

 

Additional Information in respect of the AIM Rules

 

The following information regarding the appointment of Stephen Daniel Symonds,
aged 47, is disclosed under Schedule Two paragraph (g) of the AIM Rules for
Companies:

 

 Current Directorships  Previous Directorships (within the last five years)
                        Centralabs Clinical Research Limited
                        Covance Consulting Limited
                        Covance CRS Analytics Limited
                        Covance CRS Developments Limited
                        Covance CRS International Limited
                        Covance Pharma Consulting Limited
                        Envigo CRS (Switzerland) Limited
                        Envigo CRS GmbH
                        Envigo CRS Israel Limited
                        Envigo CRS SA
                        Envigo CRS Switzerland Limited
                        Envigo Holdings Limited
                        Envigo Monitoring Limited
                        Envigo RMS (UK) Limited
                        Envigo RMS BV
                        Envigo RMS GmbH
                        Envigo RMS India Private Limited
                        Envigo RMS Israel Limited
                        Envigo RMS Sarl
                        Envigo RMS SL
                        Envigo RMS Srl
                        Envigo Ventures Limited
                        Harlan Eurasia Holdings Limited
                        Harlan Europe Holdings Limited
                        HIH Limited
                        Huntingdon Consulting Engineers Limited
                        Huntingdon Research Centre Limited
                        Labcorp Research Limited
                        Labcorp UK Limited
                        Paragon Global Services Limited
                        Pathfinder Clinical Development Limited
                        Pathfinder Nominees Limited
                        Servicepharm Limited

 

As at the date of this announcement, Stephen Symonds holds 22,950 ordinary
shares in the Company representing 0.07% of the Company's issued share
capital. In addition, Stephen holds an interest in 152,671 options over
ordinary shares of the Company.

 

Save as set out above there are no further disclosures pursuant to Rule 17 or
Schedule Two paragraph (g) of the AIM Rules for Companies in respect of the
appointment of Stephen Symonds.

 

For further information, please contact:

 

 Cambridge Cognition Holdings Plc            Tel: 01223 810 700
 Matthew Stork, Chief Executive Officer      press@camcog.com
 Stephen Symonds, Chief Financial Officer

 Panmure Gordon (UK) Ltd

 (NOMAD and Joint Broker)                    Tel: 020 78862500
 Freddy Crossley / Emma Earl / Mark Rodgers  (Corporate Advisory)
 Rupert Dearden                              (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)      Tel: 020 3903 7715
 David Poutney / James Serjeant

 IFC Advisory Ltd (Financial PR and IR)      Tel: 020 3934 6630
 Tim Metcalfe / Graham Herring / Zach Cohen  cog@investor-focus.co.uk

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAKZGGRFFMGZZM